July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Retinal thickness as biomarker in patients with amyloid proven Alzheimer’s disease
Author Affiliations & Notes
  • Frank D Verbraak
    Ophthalmology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Jurre den Haan
    Neurology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Aleid van de Kreeke
    Ophthalmology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Frederik Barkhof
    Neurology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Bart N van Berckel
    Neurology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Charlotte E Teunissen
    Neurology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Philip Scheltens
    Neurology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Pieter Jelle Visser
    Neurology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Femke H Bouwman
    Neurology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Footnotes
    Commercial Relationships   Frank Verbraak, None; Jurre den Haan, None; Aleid van de Kreeke, None; Frederik Barkhof, None; Bart N van Berckel, None; Charlotte E Teunissen, None; Philip Scheltens, None; Pieter Jelle Visser, None; Femke H Bouwman, None
  • Footnotes
    Support  Stichting Alzheimer Nederland, Stichting VUmcfonds, Stichting Dioraphte, EMIF grant number 115372, GE Healthcare
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1271. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Frank D Verbraak, Jurre den Haan, Aleid van de Kreeke, Frederik Barkhof, Bart N van Berckel, Charlotte E Teunissen, Philip Scheltens, Pieter Jelle Visser, Femke H Bouwman; Retinal thickness as biomarker in patients with amyloid proven Alzheimer’s disease. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1271. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinal thickness measured with optical coherence tomography (OCT) is hypothesized to be a non-invasive biomarker for Alzheimer’s disease (AD), but is also influenced by age-related ophthalmological disease. We therefore measured retinal thickness in well-characterized AD and control participants.

Methods : We included 57 AD cases with evidence of amyloid pathology, and 85 cognitively normal, amyloid negative controls. All subjects underwent a thorough ophthalmological assessment to exclude ocular disease, and included retinal thickness measurements with OCT.

Results : Retinal thickness did not discriminate cases from controls, also stratified for early versus late onset AD. We found significant associations between macular thickness and Global Cortical Atrophy (Beta -0.314;p=0.001) and Parietal Cortical Atrophy (Beta -0.276;p=0.003).

Conclusions : In this study, representing the largest OCT study of amyloid proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuro-imaging and CSF measures, querying the use of retinal thickness measurements as AD biomarker.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×